Glyceollins as Novel Targeted Therapeutic for the Treatment of Triple-Negative Breast Cancer
Department of Chemistry
The purpose of this study was to investigate the effects of glyceollins on the suppression of tumorigenesis in triple-negative breast carcinoma cell lines. We further explored the effects of glyceollins on microRNA and protein expression in MDA-MB-231 cells. Triple-negative (ER-, PgR-and Her2/neu-) breast carcinoma cells were used to test the effects of glyceollins on tumorigenesis in vivo. Following this procedure, unbiased microarray analysis of microRNA expression was performed. Additionally, we examined the changes in the proteome induced by glyceollins in the MDA-MB-231 cells. Tumorigenesis studies revealed a modest suppression of MDA-MB-231 and MDA-MB-468 cell tumor growth in vivo. In response to glyceollins we observed a distinct change in microRNA expression profiles and proteomes of the triple-negative breast carcinoma cell line, MDA-MB-231. Our results demonstrated that the glyceollins, previously described as anti-estrogenic agents, also exert antitumor activity in triple-negative breast carcinoma cell systems. This activity correlates with the glyceollin alteration of microRNA and proteomic expression profiles.
Rhodes, L. V.; Tilghman, S. L.; Boue, S. M.; Wang, S.; Khalili, H.; Muir, S. E.; Bratton, M. R.; Zhang, Q; Wang, Guangdi; and Burow, M. E., "Glyceollins as Novel Targeted Therapeutic for the Treatment of Triple-Negative Breast Cancer" (2012). Faculty and Staff Publications. 137.